The study aimed to find out the frequency of Cytogenetic aberrations in multiple myeloma
patients in Indian perspective.
CheckMate-602: An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma
is an incurable and life-threatening blood cancer that is characterised by tumour proliferation and suppression of the immune system.
The researchers examined the BMI of normal, overweight, obese and morbidly obese patients, and the effects on multiple myeloma
A 71-year-old man, with a background history of diabetes mellitus, hypertension and chronic kidney disease, was referred to our center for multiple myeloma
work-up as the patient had history of low back pain for two-months and was noted to have deteriorating renal function and decreasing trend of haemoglobin levels.
CoMMpass is a longitudinal study of 1,000 newly diagnosed patients with active multiple myeloma
and aims to map each of these patients' genomic profiles to clinical outcomes to develop a more complete understanding of patient responses to treatments.
Barlogie's work has led to a median survival rate of more than eight years today for Myeloma Institute patients, compared with a 34 percent five-year survival rate for multiple myeloma
patients, as documented by the NCI between 1995-2001.
The clinical manifestations of multiple myeloma
include bone pain, anemia, hypercalcemia, and renal disease.
We very quickly found out there wasn't a whole lot of information available for multiple myeloma
Today marks another historic day - the availability of an unprecedented second breakthrough therapy for this fatal disease within just seven months for patients who have run out of treatment options," stated Kathy Giusti, Founder and CEO of the MMRF and the Multiple Myeloma
Research Consortium (MMRC), and a multiple myeloma
These learnings can in turn enhance our efforts to improve disease management for people living with multiple myeloma
This trail has been initiated in conjunction with Multiple Myeloma
Research Consortium (MMRC) evaluating ganetespib, a second generation Hsp90 inhibitor being developed by Synta Pharmaceuticals (NASDAQ:SNTA).